Isavuconazonium information

Isavuconazole
Clinical data
Trade names	Cresemba
Other names	BAL8557
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth, intravenous (IV)
ATC code	J02AC05 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Identifiers
	IUPAC name 4-{2-[(1R,2R)-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-thiazol-4-yl}benzonitrile;
CAS Number	241479-67-4;
PubChem CID	6918485;
ChemSpider	5293682 ;
UNII	60UTO373KE;
KEGG	D10750 ;
ChEBI	CHEBI:85979 ;
ChEMBL	ChEMBL409153 ;
NIAID ChemDB	416566;
CompTox Dashboard (EPA)	DTXSID2058251 ;
Chemical and physical data
Formula	C22H17F2N5OS
Molar mass	437.47 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	122 °C (252 °F)
Solubility in water	14.2 ± 0.5 × 10−6 mol/L (pH 7.4)
	SMILES C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F;
	InChI InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1 ; Key:DDFOUSQFMYRUQK-RCDICMHDSA-N ;
	(what is this?) (verify)

Isavuconazonium sulfate
Clinical data
Trade names	Cresemba
AHFS/Drugs.com	Monograph
License data	US DailyMed: Isavuconazonium sulfate;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth, intravenous (IV)
ATC code	None;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	742049-41-8; sulfate: 946075-13-4 ;
ChemSpider	32701987;
UNII	VH2L779W8Q; sulfate: 31Q44514JV ;
KEGG	D10644 ; sulfate: D10643 ;
CompTox Dashboard (EPA)	DTXSID2058251 ;
Chemical and physical data
Formula	C35H35F2N8O5S
Molar mass	717.77 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](c1nc(cs1)c2ccc(cc2)C#N)[C@](Cn3c[n+](cn3)C(C)OC(=O)N(C)c4c(cccn4)COC(=O)CNC)(c5cc(ccc5F)F)O.OS(=O)(=O)[O-];
	InChI InChI=1S/C35H35F2N8O5S.H2O4S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3;1-5(2,3)4/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3;(H2,1,2,3,4)/q+1;/p-1/t22-,23?,35+;/m0./s1; Key:LWXUIUUOMSMZKJ-KLFWAVJMSA-M;
	(what is this?) (verify)

Isavuconazonium sulfate, sold under the brand name Cresemba, is a systemic antifungal medication of the triazole class which is used to treat invasive aspergillosis and mucormycosis.^[9]^[7]^[8]^[12]

The most common side effects include abnormal liver tests, nausea, vomiting, difficulty breathing, abdominal pain, diarrhea, injection site reactions, headache, low blood potassium and skin rash.^[10]

Isavuconazonium is a prodrug of isavuconazole.^[13]

^ ^a ^b "Isavuconazonium (Cresemba) Use During Pregnancy". Drugs.com. 31 January 2020. Retrieved 26 August 2020.
^ "Cresemba isavuconazole (as isavuconazonium sulfate) 200 mg powder for injection vial". Therapeutic Goods Administration (TGA). ARTG ID 305480. Archived from the original on 19 June 2022. Retrieved 5 September 2021.
^ "Cresemba isavuconazole (as isavuconazonium sulfate) 100 mg capsule blister pack". Therapeutic Goods Administration (TGA). ARTG ID 305452. Archived from the original on 5 September 2021. Retrieved 5 September 2021.
^ "AusPAR: Isavuconazole (as sulphate)". Therapeutic Goods Administration (TGA). 22 January 2020. Retrieved 5 September 2021.
^ "Regulatory Decision Summary for Cresemba". Drug and Health Product Register. 23 October 2014.
^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
^ ^a ^b "Cresemba 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 28 June 2021. Retrieved 5 September 2021.
^ ^a ^b "Cresemba 200mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 28 June 2021. Retrieved 5 September 2021.
^ ^a ^b "Cresemba- isavuconazonium sulfate capsule Cresemba- isavuconazonium sulfate injection, powder, lyophilized, for solution". DailyMed. 2 December 2019. Retrieved 26 August 2020.
^ ^a ^b Cite error: The named reference Cresemba EPAR was invoked but never defined (see the help page).
^ ^a ^b Cite error: The named reference Voronin_2021 was invoked but never defined (see the help page).
^ Donnelley MA, Zhu ES, Thompson GR (2 June 2016). "Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections". Infection and Drug Resistance. 9: 79–86. doi:10.2147/IDR.S81416. PMC 4898026. PMID 27330318.
^ Wilkes GM, Barton-Burke M (2019). 2020-2021 Oncology Nursing Drug Handbook. Jones & Bartlett Learning. pp. 1874–1876. ISBN 978-1-284-17132-7.

[Drugs.com_pregnancy-1] "Isavuconazonium (Cresemba) Use During Pregnancy". Drugs.com. 31 January 2020. Retrieved 26 August 2020.

[2] "Cresemba isavuconazole (as isavuconazonium sulfate) 200 mg powder for injection vial". Therapeutic Goods Administration (TGA). ARTG ID 305480. Archived from the original on 19 June 2022. Retrieved 5 September 2021.

[3] "Cresemba isavuconazole (as isavuconazonium sulfate) 100 mg capsule blister pack". Therapeutic Goods Administration (TGA). ARTG ID 305452. Archived from the original on 5 September 2021. Retrieved 5 September 2021.

[4] "AusPAR: Isavuconazole (as sulphate)". Therapeutic Goods Administration (TGA). 22 January 2020. Retrieved 5 September 2021.

[5] "Regulatory Decision Summary for Cresemba". Drug and Health Product Register. 23 October 2014.

[6] "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

[Cresemba_capsules_SmPC-7] "Cresemba 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 28 June 2021. Retrieved 5 September 2021.

[Cresemba_IV_SmPC-8] "Cresemba 200mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 28 June 2021. Retrieved 5 September 2021.

[Cresemba_FDA_label-9] "Cresemba- isavuconazonium sulfate capsule Cresemba- isavuconazonium sulfate injection, powder, lyophilized, for solution". DailyMed. 2 December 2019. Retrieved 26 August 2020.

[Cresemba_EPAR-10] Cite error: The named reference Cresemba EPAR was invoked but never defined (see the help page).

[Voronin_2021-11] Cite error: The named reference Voronin_2021 was invoked but never defined (see the help page).

[Donnelley2016-12] Donnelley MA, Zhu ES, Thompson GR (2 June 2016). "Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections". Infection and Drug Resistance. 9: 79–86. doi:10.2147/IDR.S81416. PMC 4898026. PMID 27330318.

[Wilkes2019-13] Wilkes GM, Barton-Burke M (2019). 2020-2021 Oncology Nursing Drug Handbook. Jones & Bartlett Learning. pp. 1874–1876. ISBN 978-1-284-17132-7.

Isavuconazonium information

and 5 Related for: Isavuconazonium information

Isavuconazonium

Prodrug

C22H17F2N5OS

Bellergal

Steroidogenesis inhibitor